-
The individual response to antibiotics and diet — insights into gut microbial resilience and host metabolism Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-03-14 Lars M. M. Vliex, John Penders, Arjen Nauta, Erwin G. Zoetendal, Ellen E. Blaak
-
Comparing Continuous Glucose Monitoring and Blood Glucose Monitoring in Adults With Inadequately Controlled, Insulin-Treated Type 2 Diabetes (Steno2tech Study): A 12-Month, Single-Center, Randomized Controlled Trial Diabetes Care (IF 16.2) Pub Date : 2024-03-15 Nanna Lind, Merete B. Christensen, Dorte L. Hansen, Kirsten Nørgaard
OBJECTIVE To compare the 12-month effects of continuous glucose monitoring (CGM) versus blood glucose monitoring (BGM) in adults with insulin-treated type 2 diabetes. RESEARCH DESIGN AND METHODS This is a single-center, parallel, open-label, randomized controlled trial including adults with inadequately controlled, insulin-treated type 2 diabetes from the outpatient clinic at Steno Diabetes Center
-
Antibodies drive adipose tissue ageing Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-03-13 Shimona Starling
The mechanisms underlying metabolic decline during ageing are not well understood. A new study in Cell Metabolism identifies IgG antibodies as factors that accumulate in white adipose tissue (WAT) during ageing, driving tissue fibrosis and impaired metabolic health in mice. “Leveraging our understanding of ageing research, we naturally sought to investigate whether interventions targeting ageing could
-
Haptoglobin Phenotype and Intensive Glycemic Control for Coronary Artery Disease Risk Reduction in People With Type 2 Diabetes: The ADVANCE Study Diabetes Care (IF 16.2) Pub Date : 2024-03-14 Leah E. Cahill, Rachel A. Warren, Allie S. Carew, Andrew P. Levy, John Sapp, Michelle Samuel, Elizabeth Selvin, Samantha K. Lavallée, Neil Poulter, Michel Marre, Stephen Harrap, Giuseppe Mancia, Katie Harris, John Chalmers, Mark Woodward, Eric B. Rimm
OBJECTIVE Intensive glycemic control reduced coronary artery disease (CAD) events among the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study participants with the haptoglobin (Hp)2-2 phenotype but not in participants without the Hp2-2 phenotype. It is unknown whether and how these results translate across different demographic/clinical characteristics and treatment strategies. RESEARCH
-
The Difference Between Cystatin C- and Creatinine-Based Estimated Glomerular Filtration Rate and Risk of Diabetic Microvascular Complications Among Adults With Diabetes: A Population-Based Cohort Study Diabetes Care (IF 16.2) Pub Date : 2024-03-12 Daijun He, Bixia Gao, Jinwei Wang, Chao Yang, Ming-Hui Zhao, Luxia Zhang
OBJECTIVE The impact of the difference between cystatin C- and creatinine-based estimated glomerular filtration rate (eGFRdiff) on diabetic microvascular complications (DMCs) remains unknown. We investigated the associations of eGFRdiff with overall DMCs and subtypes, including diabetic retinopathy (DR), diabetic kidney disease (DKD), and diabetic neuropathy (DN). RESEARCH DESIGN AND METHODS This prospective
-
Impact of Type 2 Diabetes and Glycated Hemoglobin Levels Within the Recommended Target Range on Mortality in Older Adults With Cognitive Impairment Receiving Care at a Memory Clinic: NCGG-STORIES Diabetes Care (IF 16.2) Pub Date : 2024-03-12 Taiki Sugimoto, Takashi Sakurai, Kazuaki Uchida, Yujiro Kuroda, Haruhiko Tokuda, Takuya Omura, Taiji Noguchi, Ayane Komatsu, Takeshi Nakagawa, Kosuke Fujita, Nanae Matsumoto, Rei Ono, Paul K. Crane, Tami Saito
OBJECTIVE To determine the impact of type 2 diabetes and glycated hemoglobin (HbA1c) levels within the recommended target range according to the Japan Diabetes Society/Japan Geriatrics Society Joint Committee on mortality in older adults with cognitive impairment. RESEARCH DESIGN AND METHODS This retrospective cohort study included 1,528 and 468 patients aged ≥65 years without and with type 2 diabetes
-
Gut microbiota–tryptophan metabolism–GLP-1 axis participates in β-cell regeneration induced by dapagliflozin Diabetes (IF 7.7) Pub Date : 2024-03-12 Yafei Jiang, Jin Yang, Li Xia, Tianjiao Wei, Xiaona Cui, Dandan Wang, Zirun Jin, Xiafang Lin, Fei Li, Kun Yang, Shan Lang, Ye Liu, Jing Hang, Zhe Zhang, Tianpei Hong, Rui Wei
Sodium-glucose co-transporter 2 (SGLT2) inhibitor, an efficacious anti-diabetic agent, which has cardiovascular and renal benefits, can promote pancreatic β-cell regeneration in type 2 diabetic mice. However, the underlying mechanism remains unclear. In this study, we aimed to use multi-omics to identify the mediators involved in β-cell regeneration induced by dapagliflozin. We showed that dapagliflozin
-
Polygenic Risk for Type 2 Diabetes in African Americans Diabetes (IF 7.7) Pub Date : 2024-03-12 Marguerite R. Irvin, Tian Ge, Amit Patki, Vinodh Srinivasasainagendra, Nicole D. Armstrong, Brittney Davis, Alana C Jones, Emma Perez, Lauren Stalbow, Matthew Lebo, Eimear Kenny, Ruth J.F. Loos, Maggie C. Y. Ng, Jordan W. Smoller, James B. Meigs, Leslie A. Lange, Elizabeth W. Karlson, Nita A. Limdi, Hemant K. Tiwari
African Americans (AAs) have been underrepresented in polygenic risk score (PRS) studies. Herein, we integrated genome-wide data from multiple observational studies on type 2 diabetes (T2D), encompassing a total of 101,987 AAs, to train and optimize an AA focused T2D PRS (PRSAA), using a Bayesian polygenic modeling method (PRS-CS). We further tested the score in three independent studies with a total
-
Inhibition of HSP20 ameliorates steatotic liver disease by stimulating ERK2-dependent autophagy Diabetes (IF 7.7) Pub Date : 2024-03-11 Yanli Miao, Yi Zhong, Yutian Li, Haojie Qin, Ling Yang, Guojun Cao, Yong Tang, Ting Yu, Di Fan, Yang Lu1, Jiangtong Peng, Kai Huang
Heat shock protein 20 (HSP20) emerges as a novel regulator of autophagy in the heart. Nonetheless, the detailed function of HSP20 in liver and its effect on autophagy remain unknown. Here, we observed that HSP20 expression is increased in liver tissues from mice and patients with metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD)
-
Thyroid-function reference ranges in the diagnosis of thyroid dysfunction in adults Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-03-08 Salman Razvi
Applying a uniform reference range across all adults for serum levels of thyroid stimulating hormone and thyroid hormones makes establishing a diagnosis of thyroid dysfunction challenging and could lead to potentially unnecessary treatment. For the results of thyroid function tests to be meaningful, the reference ranges should reflect individual variation in thyroid function.
-
Disparities Between Teleretinal Imaging Findings and Patient-Reported Diabetic Retinopathy Status and Follow-Up Eye Care Interval: A 10-Year Prospective Study Diabetes Care (IF 16.2) Pub Date : 2024-03-08 Paolo S. Silva, Jerry D. Cavallerano, Jennifer K. Sun, Ann M. Tolson, Dorothy Tolls, Martin J. Abrahamson, Lloyd M. Aiello, Lloyd Paul Aiello
OBJECTIVE To assess self-reported awareness of diabetic retinopathy (DR) and concordance of eye examination follow-up compared with findings from concurrent retinal images. RESEARCH DESIGN AND METHODS We conducted a prospective observational 10-year study of 26,876 consecutive patients with diabetes who underwent retinal imaging during an endocrinology visit. Awareness and concordance were evaluated
-
Pioneering new frontiers in circadian medicine chronotherapies for cardiovascular health Trends Endocrin. Met. (IF 10.9) Pub Date : 2024-03-08 Ifene David Festus, Jeri Spilberg, Martin E. Young, Sean Cain, Sepideh Khoshnevis, Michael H. Smolensky, Fariya Zaheer, Giannina Descalzi, Tami A. Martino
Cardiovascular disease (CVD) is a global health concern. Circadian medicine improves cardiovascular care by aligning treatments with our body’s daily rhythms and their underlying cellular circadian mechanisms. Time-based therapies, or chronotherapies, show special promise in clinical cardiology. They optimize treatment schedules for better outcomes with fewer side effects by recognizing the profound
-
Undiagnosed type 2 diabetes: an invisible risk factor Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-06 T, h, e, , L, a, n, c, e, t, , D, i, a, b, e, t, e, s, , &, , E, n, d, o, c, r, i, n, o, l, o, g, y
-
Metabolic remodeling in cancer and senescence and its therapeutic implications Trends Endocrin. Met. (IF 10.9) Pub Date : 2024-03-06 Yeonju Kim, Yeji Jang, Mi-Sung Kim, Chanhee Kang
Cellular metabolism is a flexible and plastic network that often dictates physiological and pathological states of the cell, including differentiation, cancer, and aging. Recent advances in cancer metabolism represent a tremendous opportunity to treat cancer by targeting its altered metabolism. Interestingly, despite their stable growth arrest, senescent cells – a critical component of the aging process
-
Itaconate in host inflammation and defense Trends Endocrin. Met. (IF 10.9) Pub Date : 2024-03-05 Dan Ye, Pu Wang, Lei-Lei Chen, Kun-Liang Guan, Yue Xiong
Immune cells undergo rapid and extensive metabolic changes during inflammation. In addition to contributing to energetic and biosynthetic demands, metabolites can also function as signaling molecules. Itaconate (ITA) rapidly accumulates to high levels in myeloid cells under infectious and sterile inflammatory conditions. This metabolite binds to and regulates the function of diverse proteins intracellularly
-
Controlling brown adipose tissue size through EPAC1 Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-03-04 Francesc Villarroya, Marta Giralt
-
Bariatric tourism Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-04 T, a, l, h, a, , B, u, r, k, i
-
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-04 P, a, u, l, i, n, a, , S, a, l, m, i, n, e, n
-
Optimising zoledronate treatment holiday duration without loss of fracture prevention Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-04 M, a, t, t, h, e, w, , T, , D, r, a, k, e
-
Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass at 5 years (YOMEGA): a prospective, open-label, non-inferiority, randomised extension study Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-04 Prof Maud Robert MD, Tigran Poghosyan MD, Prof Delphine Maucort-Boulch MD, Dr Alexandre Filippello MD, Prof Robert Caiazzo MD, Adrien Sterkers MD, Lita Khamphommala MD, Prof Fabian Reche MD, Vincent Malherbe MD, Adriana Torcivia MD, Toufic Saber MD, Dominique Delaunay PhD, Carole Langlois-Jacques MSc, Augustin Suffisseau MD, Sylvie Bin MD, Prof Emmanuel Disse MD, Prof François Pattou MD
The multicentre randomised trial YOMEGA () comparing the one anastomosis gastric bypass (OAGB) with the Roux-en-Y gastric bypass (RYGB) confirmed the non-inferiority of OAGB on weight loss outcomes at 24 months. We aimed to report weight loss, metabolic, and safety outcomes at 5 years. YOMEGA is a prospective, open-label, non-inferiority, randomised trial conducted at nine centres in France. Inclusion
-
Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-04 Prof Ian R Reid MD, Anne M Horne MBChB, Borislav Mihov BPhty, Usha Bava MHSc, Angela Stewart RN, Gregory D Gamble MSc
We previously identified that zoledronate administered at 18-month intervals reduced fragility fractures by a third in a 6-year trial of women older than 65 years with osteopenia. This extension aims to identify the persistence of these effects. Of the 2000 ambulant, community dwelling, postmenopausal women older than 65 years recruited in Auckland, New Zealand, with T-scores at the total hip or femoral
-
Cryo-electron microscopy for GPCR research and drug discovery in endocrinology and metabolism Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-02-29 Jia Duan, Xin-Heng He, Shu-Jie Li, H. Eric Xu
-
Natural History of Type 2 Diabetes in Indians: Time to Progression Diabetes Care (IF 16.2) Pub Date : 2024-03-01 K. M. Venkat Narayan, Dimple Kondal, Howard H. Chang, Deepa Mohan, Unjali P. Gujral, Ranjit Mohan Anjana, Lisa R. Staimez, Shivani A. Patel, Mohammed K. Ali, Dorairaj Prabhakaran, Nikhil Tandon, Viswanathan Mohan
OBJECTIVE To describe the natural history of diabetes in Indians. RESEARCH DESIGN AND METHODS Data are from participants older than 20 years in the Centre for Cardiometabolic Risk Reduction in South Asia longitudinal study. Glycemic states were defined per American Diabetes Association criteria. Markov models were used to estimate annual transition probabilities and sojourn time through states. RESULTS
-
Dysregulated 24 h melatonin secretion associated with intrinsically photosensitive retinal ganglion cell function in diabetic retinopathy: a cross-sectional study Diabetol. (IF 8.2) Pub Date : 2024-02-27 Sirimon Reutrakul, Jason C. Park, J. Jason McAnany, Felix Y. Chau, Kirstie K. Danielson, Bharati Prasad, Andrew Cross, Stephanie Sintetas, Julie Law, Silvana Pannain, Sarida Pratuangtham, Eve Van Cauter, Erin C. Hanlon
-
Elevated ITGA1 levels in type 2 diabetes: implications for cardiac function impairment Diabetol. (IF 8.2) Pub Date : 2024-02-27 Mengqi Su, Yilin Hou, Sidong Cai, Wenpeng Li, Yinxia Wei, Run Wang, Min Wu, Mingya Liu, Junlei Chang, Kelaier Yang, Kaihang Yiu, Cong Chen
-
Circulating metabolomic markers linking diabetic kidney disease and incident cardiovascular disease in type 2 diabetes: analyses from the Hong Kong Diabetes Biobank Diabetol. (IF 8.2) Pub Date : 2024-02-27 Qiao Jin, Eric S. H. Lau, Andrea O. Luk, Claudia H. T. Tam, Risa Ozaki, Cadmon K. P. Lim, Hongjiang Wu, Elaine Y. K. Chow, Alice P. S. Kong, Heung Man Lee, Baoqi Fan, Alex C. W. Ng, Guozhi Jiang, Ka Fai Lee, Shing Chung Siu, Grace Hui, Chiu Chi Tsang, Kam Piu Lau, Jenny Y. Leung, Man-wo Tsang, Elaine Y. N. Cheung, Grace Kam, Ip Tim Lau, June K. Li, Vincent T. F. Yeung, Emmy Lau, Stanley Lo, Samuel
-
Evolving liver disease insights from NAFLD to MASLD Trends Endocrin. Met. (IF 10.9) Pub Date : 2024-02-29 Xiude Fan, Yongfeng Song, Jiajun Zhao
The recent renaming of ‘non-alcoholic fatty liver disease’ (NAFLD) to ‘metabolic dysfunction-associated steatotic liver disease’ (MASLD) emphasizes metabolic dysfunction in steatotic liver disease and advocates for tailored, comprehensive treatment strategies, driving forward the development of personalized care and innovative therapeutic approaches.
-
Nucleosides are overlooked fuels in central carbon metabolism Trends Endocrin. Met. (IF 10.9) Pub Date : 2024-02-29 Abigail Strefeler, Joan Blanco-Fernandez, Alexis A. Jourdain
From our daily nutrition and synthesis within cells, nucleosides enter the bloodstream and circulate throughout the body and tissues. Nucleosides and nucleotides are classically viewed as precursors of nucleic acids, but recently they have emerged as a novel energy source for central carbon metabolism. Through catabolism by nucleoside phosphorylases, the ribose sugar group is released and can provide
-
Parathyroid hormone–PTH1R signaling in cardiovascular disease and homeostasis Trends Endocrin. Met. (IF 10.9) Pub Date : 2024-02-29 Dwight A. Towler
Primary hyperparathyroidism (pHPT) afflicts our aging population with an incidence approaching 50 per 100 000 patient-years at a female:male ratio of ~3:1. Decisions surrounding surgical management are currently driven by age, hypercalcemia severity, presence of osteoporosis, renal insufficiency, or hypercalciuria with or without nephrolithiasis. Cardiovascular (CV) disease (CVD) is not systematically
-
Vitamin K-dependent carboxylation in β-cells and diabetes Trends Endocrin. Met. (IF 10.9) Pub Date : 2024-02-29 Julie Lacombe, Mathieu Ferron
Vitamin K is an essential micronutrient and a cofactor for the enzyme γ-glutamyl carboxylase, which adds a carboxyl group to specific glutamic acid residues in proteins transiting through the secretory pathway. Higher vitamin K intake has been linked to a reduced incidence of type 2 diabetes (T2D) in humans. Preclinical work suggests that this effect depends on the γ-carboxylation of specific proteins
-
Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors Trends Endocrin. Met. (IF 10.9) Pub Date : 2024-02-29 Mona Mashayekhi, Bilgunay Ilkin Safa, Matthew S.C. Gonzalez, Sangwon F. Kim, Justin B. Echouffo-Tcheugui
Inflammation plays an essential role and is a common feature in the pathogenesis of many chronic diseases. The exact mechanisms through which sodium-glucose cotransporter-2 (SGLT2) inhibitors achieve their much-acclaimed clinical benefits largely remain unknown. In this review, we detail the systemic and tissue- or organ-specific anti-inflammatory effects of SGLT2 inhibitors using evidence from animal
-
Current status and future trends of the global burden of MASLD Trends Endocrin. Met. (IF 10.9) Pub Date : 2024-02-29 Lei Miao, Giovanni Targher, Christopher D. Byrne, Ying-Ying Cao, Ming-Hua Zheng
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most common chronic liver disease globally, affecting more than a third of the world's adult population. This comprehensive narrative review summarizes the global incidence and prevalence rates of MASLD and its related adverse hepatic and extrahepatic outcomes. We also discuss the substantial economic burden of MASLD
-
An historical step in our understanding of hypothalamic oestrogen feedback Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-02-28 Erik Hrabovszky
In 1957, Béla Flerkó and János Szentágothai implanted ovarian and liver tissue autografts into two distinct hypothalamic regions or the adenohypophysis of female rats. The tiny pieces of liver were absorbed. By contrast, the ovary implants survived and continued to release oestrogens. Furthermore, when the ovarian tissue was implanted below the hypothalamic paraventricular nucleus, the weight of the
-
Placental inflammation, oxidative stress, and fetal outcomes in maternal obesity Trends Endocrin. Met. (IF 10.9) Pub Date : 2024-02-28 Cindy X.W. Zhang, Alejandro A. Candia, Amanda N. Sferruzzi-Perri
The obesity epidemic has led to a growing body of research investigating the consequences of maternal obesity on pregnancy and offspring health. The placenta, traditionally viewed as a passive intermediary between mother and fetus, is known to play a critical role in modulating the intrauterine environment and fetal development, and we now know that maternal obesity leads to increased inflammation
-
Current status and future perspectives of FGF21 analogues in clinical trials Trends Endocrin. Met. (IF 10.9) Pub Date : 2024-02-28 Zara Siu Wa Chui, Qing Shen, Aimin Xu
Recent advances in fibroblast growth factor 21 (FGF21) biology and pharmacology have led to the development of several long-acting FGF21 analogues and antibody-based mimetics now in various phases of clinical trials for the treatment of obesity-related metabolic comorbidities. The efficacy of these FGF21 analogues/mimetics on glycaemic control and weight loss is rather mild and inconsistent; nevertheless
-
Interferons are key cytokines acting on pancreatic islets in type 1 diabetes Diabetol. (IF 8.2) Pub Date : 2024-02-26 Alexandra Coomans de Brachène, Maria Ines Alvelos, Florian Szymczak, Priscila L. Zimath, Angela Castela, Bianca Marmontel de Souza, Arturo Roca Rivada, Sandra Marín-Cañas, Xiaoyan Yi, Anne Op de Beeck, Noel G. Morgan, Sebastian Sonntag, Sayro Jawurek, Alexandra C. Title, Burcak Yesildag, François Pattou, Julie Kerr-Conte, Eduard Montanya, Montserrat Nacher, Lorella Marselli, Piero Marchetti, Sarah
-
Incidence trend of type 2 diabetes from 2012 to 2021 in Germany: an analysis of health claims data of 11 million statutorily insured people Diabetol. (IF 8.2) Pub Date : 2024-02-26 Carolin T. Lehner, Marian Eberl, Ewan Donnachie, Luana F. Tanaka, Gunther Schauberger, Florian Schederecker, Sebastian Himmler, Leonie Sundmacher, Stefanie J. Klug
-
Cardiovascular risk management among individuals with type 2 diabetes and severe mental illness: a cohort study Diabetol. (IF 8.2) Pub Date : 2024-02-26 Jonne G. ter Braake, Kelly J. Fleetwood, Rimke C. Vos, Luke Blackbourn, Stuart J. McGurnaghan, Sarah H. Wild, Caroline A. Jackson
-
Exploring Factors That Influence Postexercise Glycemia in Youth With Type 1 Diabetes in the Real World: The Type 1 Diabetes Exercise Initiative Pediatric Study (T1DEXIP) Diabetes Care (IF 16.2) Pub Date : 2024-02-27 Jennifer L. Sherr, Simon Bergford, Robin L. Gal, Mark A. Clements, Susana R. Patton, Peter Calhoun, Lindsey C. Beaulieu, Michael C. Riddell
OBJECTIVE To explore 24-h postexercise glycemia and hypoglycemia risk, data from the Type 1 Diabetes Exercise Initiative Pediatric (T1DEXIP) study were analyzed to examine factors that may influence glycemia. RESEARCH DESIGN AND METHODS This was a real-world observational study with participant self-reported physical activity, food intake, and insulin dosing (multiple daily injection users). Heart
-
Cardiovascular and Kidney Risks in Individuals With Type 2 Diabetes: Contemporary Understanding With Greater Emphasis on Excess Adiposity Diabetes Care (IF 16.2) Pub Date : 2024-02-27 Naveed Sattar, Calum Presslie, Martin K. Rutter, Darren K. McGuire
In high-income countries, rates of atherosclerotic complications in type 2 diabetes have declined markedly over time due to better management of traditional risk factors including lipids, blood pressure and glycemia levels. Population-wide reductions in smoking have also helped lower atherosclerotic complications and so reduce premature mortality in type 2 diabetes. However, as excess adiposity is
-
Accuracy and Feasibility of Real-time Continuous Glucose Monitoring in Critically Ill Patients After Abdominal Surgery and Solid Organ Transplantation Diabetes Care (IF 16.2) Pub Date : 2024-02-27 Barbora Voglová Hagerf, Marek Protus, Lenka Nemetova, Milos Mraz, Eva Kieslichova, Eva Uchytilova, Veronika Indrova, Jan Lelito, Peter Girman, Martin Haluzík, Janka Franekova, Veronika Svirlochova, David C. Klonoff, Michael A. Kohn, Antonin Jabor
OBJECTIVE Glycemia management in critical care is posing a challenge in frequent measuring and adequate insulin dose adjustment. In recent years, continuous glucose measurement has gained accuracy and reliability in outpatient and inpatient settings. The aim of this study was to assess the feasibility and accuracy of real-time continuous glucose monitoring (CGM) in ICU patients after major abdominal
-
Mitochondrial dysfunction in lipid processing and gastrointestinal disorders Trends Endocrin. Met. (IF 10.9) Pub Date : 2024-02-27 Yan Hu, Hao Huang, Rong Xiang
Mitochondrial dysfunctions predominantly cause encephalomyopathies with muscle atrophy and neurodegeneration. However, their impact on other tissues, particularly the gastrointestinal tract, requires further investigation. In a recent report in , used mice deficient in the mitochondrial aminoacyl-tRNA synthetase DARS2 to investigate the role of enterocytic mitochondria in dietary lipid processing and
-
Low birthweight and overweight during childhood and young adulthood and the risk of type 2 diabetes in men: a population-based cohort study Diabetol. (IF 8.2) Pub Date : 2024-02-22 Jimmy Célind, Maria Bygdell, Rebecka Bramsved, Jari Martikainen, Claes Ohlsson, Jenny M. Kindblom
-
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes Diabetol. (IF 8.2) Pub Date : 2024-02-22 Pedro Cardoso, Katie G. Young, Anand T. N. Nair, Rhian Hopkins, Andrew P. McGovern, Eram Haider, Piyumanga Karunaratne, Louise Donnelly, Bilal A. Mateen, Naveed Sattar, Rury R. Holman, Jack Bowden, Andrew T. Hattersley, Ewan R. Pearson, Angus G. Jones, Beverley M. Shields, Trevelyan J. McKinley, John M. Dennis
-
Phase I results for AMG 133 Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-02-22 Claire Greenhill
The past few years have seen a rapid increase in the development and use of new drugs to treat obesity, many of which target the incretin system. A new study has reported the phase I results of AMG 133 (also known as maridebart cafraglutide), which is a bispecific molecule consisting of a glucose-dependent insulinotropic peptide receptor (GIPR) antagonist antibody conjugated to two glucagon-like peptide
-
Endocrine disrupting chemicals are a threat to hormone health: a commentary on behalf of the ESE Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-02-22 Martin Reincke, Wiebke Arlt, Pauliina Damdimopoulou, Josef Köhrle, Jerome Bertherat
The European Society of Endocrinology (ESE), representing 20,000 endocrinologists, is concerned about the effect of endocrine disrupting chemicals (EDCs) on endocrine health, particularly thyroid and gonadal function. The policy strategies of the ESE aim to minimize overall exposure of humans to EDCs and to stimulate funding for research at the level of the European Union.
-
A Diabetes Pregnancy Technology Roadmap: The 2023 Norbert Freinkel Award Lecture Diabetes Care (IF 16.2) Pub Date : 2024-02-23 Helen R. Murphy
Norbert Freinkel emphasized the need for “more aggressive therapy with exogenous insulin” during type 1 diabetes (T1D) pregnancy. Recent advances in diabetes technology, continuous glucose monitoring (CGM), and hybrid closed-loop (HCL) insulin delivery systems allow us to revisit Freinkel’s observations from a contemporary perspective. The Continuous Glucose Monitoring in Women With Type 1 Diabetes
-
Estimating Glycemia From HbA1c and CGM: Analysis of Accuracy and Sources of Discrepancy Diabetes Care (IF 16.2) Pub Date : 2024-02-23 Veronica Tozzo, Matthew Genco, Shammah O. Omololu, Christopher Mow, Hasmukh R. Patel, Chhaya H. Patel, Samantha N. Ho, Evie Lam, Batoul Abdulsater, Nikita Patel, Robert M. Cohen, David M. Nathan, Camille E. Powe, Deborah J. Wexler, John M. Higgins
OBJECTIVE To examine the accuracy of different periods of continuous glucose monitoring (CGM), hemoglobin A1c (HbA1c), and their combination for estimating mean glycemia over 90 days (AG90). RESEARCH DESIGN AND METHODS We retrospectively studied 985 CGM periods of 90 days with <10% missing data from 315 adults (86% of whom had type 1 diabetes) with paired HbA1c measurements. The impact of mean red
-
Waking Up to the Importance of Sleep in Type 2 Diabetes Management: A Narrative Review Diabetes Care (IF 16.2) Pub Date : 2024-02-23 Joseph Henson, Alix Covenant, Andrew P. Hall, Louisa Herring, Alex V. Rowlands, Thomas Yates, Melanie J. Davies
For the first time, the latest American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) consensus guidelines have incorporated a growing body of evidence linking health outcomes associated with type 2 diabetes to the movement behavior composition over the whole 24-h day. Of particular note, the importance of sleep as a key lifestyle component in the management of type
-
GRP78 contributes to the beneficial effects of SGLT2 inhibitor on proximal tubular cells in DKD Diabetes (IF 7.7) Pub Date : 2024-02-23 Atsuko Nakatsuka, Satoshi Yamaguchi, Jun Wada
Beneficial effects of SGLT2 inhibitors on kidney function are well-known; however, their molecular mechanisms are not fully understood. We focused on 78 kDa glucose-regulated protein (GRP78) and its interaction with SGLT2 and Integrin ß1 beyond the chaperone property of GRP78. In STZinduced diabetic mouse kidneys, GRP78, SGLT2, and Integrin ß1 increased in the plasma membrane fraction, while they were
-
TRIB2-mediated modulation of AMPK promotes hepatic insulin resistance Diabetes (IF 7.7) Pub Date : 2024-02-23 Dan Wang, Xiaonan Kang, Lu Zhang, Yaoyao Guo, Ziyin Zhang, Huihui Ren, Gang Yuan
Insulin resistance and its linked health complications are increasing in prevalence. Recent work has caused the role of Tribbles2 (TRIB2) in metabolism and cellular signaling to be increasingly appreciated, but its role in the progression of insulin resistance has not been elucidated. Here, we explore the functions of TRIB2 in modulating insulin resistance and the mechanism involved in insulin resistance
-
Macrophage SHP2 Deficiency Alleviates Diabetic Nephropathy via Suppression of MAPK/NF-ĸB-Dependent Inflammation Diabetes (IF 7.7) Pub Date : 2024-02-23 Xue Han, Jiajia Wei, Ruyi Zheng, Yu Tu, Mengyang Wang, Lingfeng Chen, Zheng Xu, Lei Zheng, Chao Zheng, Qiaojuan Shi, Huazhong Ying, Guang Liang
Increasing evidence implicates chronic inflammation as the main pathological cause of diabetic nephropathy (DN). Exploration of key targets in the inflammatory pathway may provide new treatment options for DN. Here, we aim to investigate the role of Src Homology 2 Containing Protein Tyrosine Phosphatase 2 (SHP2) in macrophages and its association with DN. The upregulated phosphorylation of SHP2 was
-
Coagulation factor FVII fine-tunes hepatic steatosis by blocking AKT-CD36-mediated fatty acid uptake Diabetes (IF 7.7) Pub Date : 2024-02-23 Yao Zhang, Quanxin Jiang, Xingxing Liang, Qiqi Qian, Jie Xiong, Chuchu Liu, Junting Xu, Ning Wang, Ying Xu, Peihui Zhou, Sijia Lu, Qian Zhou, Yanmei Yuan, Xuemei Fan, Junli Liu, Suzhen Chen
NAFLD is considered as a risk factor for cardiovascular and cerebrovascular disease owing to its close association with coagulant disturbances. However, the precise biological functions and mechanisms that connect coagulation factors to NAFLD pathology remain inadequately understood. Herein, with unbiased bioinformatic analyses followed by functional test, we demonstrate that hepatic expression of
-
Multi-omics Analyses Identify AKR1A1 as a Biomarker for Diabetic Kidney Disease Diabetes (IF 7.7) Pub Date : 2024-02-23 DengFeng Li, Fang-Chi Hsu, Nicholette D. Palmer, Liang Liu, Young A Choi, Mariana Murea, John S. Parks, Donald W. Bowden, Barry I. Freedman, Lijun Ma
Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease. As many genes associate with DKD, multi-omics approaches were employed to narrow the list of functional genes, gene products and related pathways providing insights into the pathophysiological mechanisms of DKD. The Kidney Precision Medicine Project human kidney single-cell RNA-sequencing (scRNAseq) dataset and Mendeley
-
Disparities in Acute and Chronic Complications of Diabetes Along the U.S. Rural-Urban Continuum Diabetes Care (IF 16.2) Pub Date : 2024-02-22 Kyle Steiger, Jeph Herrin, Kavya Sindhu Swarna, Esa M. Davis, Rozalina G. McCoy
OBJECTIVE To determine the relative hazards of acute and chronic diabetes complications among people with diabetes across the U.S. rural-urban continuum. RESEARCH DESIGN AND METHODS This retrospective cohort study used the OptumLabs Data Warehouse, a deidentified data set of U.S. commercial and Medicare Advantage beneficiaries, to follow 2,901,563 adults (age ≥18 years) with diabetes between 1 January
-
Historic Redlining and Impact of Structural Racism on Diabetes Prevalence in a Nationally Representative Sample of U.S. Adults Diabetes Care (IF 16.2) Pub Date : 2024-02-22 Leonard E. Egede, Rebekah J. Walker, Jennifer A. Campbell, Sebastian Linde
OBJECTIVE We investigated direct and indirect relationships between historic redlining and prevalence of diabetes in a U.S. national sample. RESEARCH DESIGN AND METHODS Using a previously validated conceptual model, we hypothesized pathways between structural racism and prevalence of diabetes via discrimination, incarceration, poverty, substance use, housing, education, unemployment, and food access
-
Socioeconomic Deprivation and the Risk of Sight-Threatening Diabetic Retinopathy (STDR): A Population-Based Cohort Study in the U.K. Diabetes Care (IF 16.2) Pub Date : 2024-02-22 Luyuan Tan, Jingya Wang, Jieun Han, Christopher Sainsbury, Alastair K. Denniston, Francesca L. Crowe, Konstantinos A. Toulis, Muhammad Ali Karamat, Mi Yao, Krishnarajah Nirantharakumar
OBJECTIVE To evaluate the associations between socioeconomic deprivation and sight-threatening diabetic retinopathy (STDR) in individuals with type 1 (T1D) and type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS Data from 175,628 individuals with diabetes in the Health Improvement Network were used to assess the risk of STDR across Townsend Deprivation Index quantiles using Cox proportional hazard regression
-
Lysine lactylation in the regulation of tumor biology Trends Endocrin. Met. (IF 10.9) Pub Date : 2024-02-22 Zijian Yang, Yingqi Zheng, Qiang Gao
Lysine lactylation (Kla), a newly discovered post-translational modification (PTM) of lysine residues, is progressively revealing its crucial role in tumor biology. A growing body of evidence supports its capacity of transcriptional regulation through histone modification and modulation of non-histone protein function. It intricately participates in a myriad of events in the tumor microenvironment
-
Brief Review and Perspective: Antioxidants for early treatment of Type 2 Diabetes in Rodents and Humans: Lost in Translation? Diabetes (IF 7.7) Pub Date : 2024-02-22 R. Paul Robertson
Reactive oxygen species (ROS) are formed by virtually all tissues. In normal concentrations they facilitate many physiologic activities, but in excess they cause oxidative stress and tissue damage. Local antioxidant enzyme synthesis in cells is regulated by the cytoplasmic KEAP-1/ Nrf2 complex, which is stimulated by ROS, to release Nrf2 for entry into the nucleus where it upregulates antioxidant gene
-
Cell-surface ZnT8 antibody prevents and reverses autoimmune diabetes in mice Diabetes (IF 7.7) Pub Date : 2024-02-22 Devi Kasinathan, Zheng Guo, Dylan C. Sarver, G. William Wong, Shumei Yun, Aaron W. Michels, Liping Yu, Chandan Sona, Matthew N. Poy, Maria L. Golson, Dax Fu
Type 1 diabetes (T1D) is an autoimmune disease where pathogenic lymphocytes target autoantigens expressed in the pancreatic islets, leading to the destruction of insulin-producing β-cells. Zinc transporter 8 (ZnT8) is a major autoantigen abundantly present on the β-cell surface. This unique molecular target offers the potential to shield β-cells against autoimmune attacks in T1D. Our previous work